Sign In
Buy ICCM
$0.152
+0.0127 (+9.14%)
At Close: Jun 03, 2026
ProSense® systems are being sold and installed at new locations across North America, including some of the most highly regarded medical institutions in the United States CAESAREA, Israel , Dec. 17,
Abstracts presented include 3 studies involving 263 patients, adding to a growing body of evidence across diverse patient populations supporting broader adoption of ProSense® CAESAREA, Israel , Dec.
IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes
08:30am, Friday, 05'th Dec 2025
Cryogenic flow control enhances the efficacy and precision of cryoablation procedures Robust IP portfolio becomes increasingly strategic as global interest in IceCure's platform and next-generation
IceCure Medical Ltd (ICCM) Q3 2025 Earnings Call Transcript
12:53pm, Wednesday, 19'th Nov 2025
IceCure Medical Ltd ( ICCM ) Q3 2025 Earnings Call November 19, 2025 10:00 AM EST Company Participants Eyal Shamir - CEO & Director Ronen Tsimerman - Chief Financial Officer Conference Call Participan
IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025
08:54am, Wednesday, 19'th Nov 2025
Momentum building in the U.S. and rising interest globally following landmark FDA marketing authorization for local cryoablation treatment of low-risk breast cancer Demand for ProSense® systems expec
This latest approval further broadens global access to ProSense® and supports IceCure's commercial momentum following the U.S. Food and Drug Administration's ("FDA") recent marketing authorization of
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
04:30pm, Friday, 14'th Nov 2025
CAESAREA, Israel , Nov. 14, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an opt
IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025
08:30am, Wednesday, 12'th Nov 2025
CAESAREA, Israel , Nov. 12, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that dest
IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction
08:30am, Monday, 10'th Nov 2025
Mr. Levav's appointment ensures seamless and focused organizational structure as Company expands commercial activities in the U.S. following FDA marketing clearance for ProSense® CAESAREA, Israel , N
5-year overall survival (OS) rate for stereotactic body radiation therapy (SBRT) followed by cryoablation was 74%, compared to published studies reporting 5-year OS of 41% - 52% with SBRT alone SBRT
FDA's marketing authorization for ProSense® for low-risk breast cancer received following the TME Fall Summit—Marketing authorization expected to further drive commercial traction based on the hig
IceCure Medical to Attend the 2025 Maxim Growth Summit
08:30am, Thursday, 09'th Oct 2025
IceCure recently achieved a significant milestone—ProSense® Cryoablation system became the first and only medical device to be granted FDA marketing authorization for the local treatment of breast
IceCure Medical Ltd - Special Call
11:25am, Monday, 06'th Oct 2025
IceCure Medical Ltd - Special Call Company Participants Eyal Shamir - CEO & Director Shad Good Ronen Tsimerman - CFO & COO Conference Call Participants Michael Polyviou - EVC Group Inc. Anthony Vendet
ICCM Shares Rise as FDA Clears ProSense for Breast Cancer Treatment
11:21am, Monday, 06'th Oct 2025
IceCure Medical shares surge after FDA clears ProSense, marking the first minimally invasive breast cancer treatment for women aged 70 and above.
ProSense ® cryoablation offers the choice of a minimally invasive outpatient procedure that destroys tumors by freezing without surgical removal of breast tissue First new innovation in the local
